Breaking News

Apple enters a new era in digital health with Parkinson's apps

October 24, 2023
katie-p-avatar-teal
Health Tech Correspondent

Katie here, filling in for Mohana after a great week at STAT headquarters in Boston for our Summit. Mario teased my panel on pitting ChatGPT against one brave doctor on stage last week — read or watch the drama unfold below! And reach out with any news: katie.palmer@statnews.com

watch this space

A long-awaited era in Apple's health history is here

The Apple Watch is now being leveraged to help manage Parkinson's disease, a degenerative brain disorder that affects as many as a million Americans. Over the past year, the Food and Drug Administration has cleared three Apple Watch apps from developers to track the tremors and dyskinesia associated with Parkinson's — work that began nearly a decade ago. 

The goal is to help inform treatment decisions for people and providers, but there's a long slog ahead before doctors and the broader health system can be convinced the tools are worth using. Read Mario's special report on the consumer tech giant's slow inroads in digital health through the lens of a unique disorder.


Budget lines

Time to get picky about health tech investments

After a period of intense optimism and investment — which has left some companies hanging on for dear life after going public at massive overvaluations — investors are course-correcting. Health tech investment dropped by nearly half last year from close to $30 billion in 2021, and the contraction is continuing, with $8.6 billion flowing into health tech startups so far this year. 

"There's a high bar in terms of metrics for funding," said Sofia Guerra, a vice president at Bessemer Venture Partners, which recently published its first analysis of the health tech industry. Read more analysis from Guerra and a crop of VCs who spoke with Mohana about responsible growth and looming consolidation.


artificial intelligence

A surge in market-authorized AI devices

The FDA updated its list of artificial intelligence and machine learning-enabled medical tools on Thursday, giving insight into the growth of a device class that remains poorly regulated. The list was first published in 2021, after a STAT investigation found that the agency had failed to keep the public informed on its regulation of AI devices. The FDA's pace of authorizations slowed during the pandemic, but it's revved up this year with 108 added since January. At that rate, 2023 will see authorizations increase more than 30% over last year.


general intelligence

In other FDA news...

  • On Monday, the FDA made a major update to its public-facing database for medical device adverse event reports. MAUDE and its API will now include patient age, weight, ethnicity, and race, along with the existing fields used to report device-related injuries, malfunctions, and deaths. 
  • The agency issued a warning for patients and providers about the risks of compounded ketamine. STAT has previously reported on the risks of at-home use of the drug, which is increasingly marketed by telehealth companies for off-label treatment of mental health disorders. 

demos

Doctor vs. ChatGPT

Generative AI is far from ready for primetime in medicine. But with hospitals already putting the technology to the test in their clinicopathological conferences, we decided to run our own (very unscientific) experiment at the STAT Summit in Boston last week. Ann Woolley, an infectious disease specialist from Brigham and Women's Hospital, worked to diagnose two different patient cases — including written histories and medical images — while ChatGPT churned out its answers on a screen beside her. 

We can easily declare Woolley the victor in this match-up, though the bot performed surprisingly well on a complex case of a secondary infection in a patient being treated for multiple myeloma. Read more to find where it stumbled, or watch the whole demo on STAT's YouTube channel.  



digital health

Bits of business news

  • Queer and trans-focused digital health company Folx changed its model in August to allow some patients to use insurance for care; it announced its in-network health plans, including Blue Shield of California, last week. Insured patients will pay a $40 monthly membership fee with their copays, and uninsured patients can still pay cash for visits and prescriptions. 
  • Vitamin and supplement retailer GNC jumped on the direct-to-consumer virtual health bandwagon with subscription plans ranging from $35 a year to $40 a month. They offer unlimited virtual-only care for urgent needs (pink eye), 'lifestyle' needs (hair loss), primary care (high cholesterol), mental health care, and physical therapy.  

More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading


Thanks for reading! More on Thursday - Katie

Katie Palmer 


Enjoying STAT Health Tech? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments